Key facts
- This page summarizes Sean Maduck's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Nov 2026, 19:26.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options Exercise
Sale
Sale
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Section 16 status
Sean Maduck is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Footnote F2
This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
Footnote F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.12 to $82.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.25 to $82.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.34 to $83.02 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Footnote F6
Reflects a transfer of shares of Common Stock between direct and indirect accounts over which the Reporting Person has beneficial ownership. The transfer resulted only in a change in the form of the Reporting Person's beneficial ownership and is exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934, as amended.
Footnote F7
Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
Footnote F8
Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
Footnote F9
Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Footnote F10
Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Footnote F11
Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Footnote F12
Represents the shares held by SNM 2026-2 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
Footnote F13
Fully exercisable.
SEC remarks
Former President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.